Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131
PharmaEssentia USA Corporation (“PharmaEssentia”) provides the following information to Colorado prescribers and pharmacists pursuant to Colorado House Bill 19-1131 (“HB 19-1131”) in connection with prescription drug marketing activities. The price listed below is Wholesale Acquisition Cost (“WAC”) established and made available to the public by a third-party publisher.
| NDC | Product Name | Strength | Package Size | WAC Price |
|---|---|---|---|---|
| 73536-500-01 | BESREMi® (ropeginterferon alfa-2b- njft) | 500 mcg/ml | 1 syringe | $10,421 USD |
Generic Prescription Drugs from the same therapeutic class (as defined by HB 19-1131): None
The price listed is WAC price, which represents PharmaEssentia’s published wholesale list price for the product before any discount, rebate, or other price reduction. The WAC price listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of the products listed.
Pricing information listed does not imply safety or efficacy of the product. Please refer to the product’s FDA-approved label and indication for further information at:
https://us.pharmaessentia.com/downloads/Besremi_USPI_ENG.pdf
Data as of May 15, 2026
© 2026 PharmaEssentia Corporation. All rights reserved. BESREMi, the BESREMi logo, and PharmaEssentia are registered trademarks of PharmaEssentia Corporation.
US-BSRM-2100194 (v11.0) 05/2026